Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Atorvaliq (atorvastatin calcium) is the first and only FDA-approved oral liquid Suspension that is indicated for the treatment of high cholesterol and certain risk factors for heart disease or stroke.
Lead Product(s): Atorvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atorvaliq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2023
Details:
Liqrev (sildenafil) is the PDE5 inhibitor and First and Only Ready-made FDA-approved Liquid Suspension is indicated for the treatment of pulmonary arterial hypertension.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Liqrev
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
Potassium phosphate injection is a phosphate replacement that is used to treat or prevent hypophosphatemia (low phosphorus in the blood).
Lead Product(s): Potassium Phosphate
Therapeutic Area: Nutrition and Weight Loss Product Name: Potassium Phosphate-Geneic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2023
Details:
Tadliq is the first and only FDA-approved liquid oral suspension of tadalafil for adult patients with difficulty swallowing. Tadliq is indicated for the treatment of pulmonary arterial hypertension and ensures consistent dosing.
Lead Product(s): Tadalafil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Tadliq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
Norliqva (Amlodipine) oral solution, 1 mg/mL, first and only FDA-approved oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker, for treatment of hypertension in patients 6 years of age and older.
Lead Product(s): Amlodipine Besylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Norliqva
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022